H. Benlalam, N. Labarriere, B. Linard, L. Derre, E. Diez et al., Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma inWltrating lymphocytes (TIL): implications for immunotherapy, Eur J Immunol, vol.31, pp.2007-2015, 2001.

H. Benlalam, B. Linard, Y. Guilloux, A. Moreau-aubry, L. Derre et al., Identi-Wcation of Wve new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-inWltrating lymphocytes, J Immunol, vol.171, pp.6283-6289, 2003.

M. Bodinier, M. A. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., EYcient detection and immunomagnetic sorting of speciWc T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat Med, vol.6, pp.707-710, 2000.

V. Brichard, A. Van-pel, T. Wolfel, C. Wolfel, E. De-plaen et al., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J Exp Med, vol.178, pp.489-495, 1993.

P. G. Coulie, V. Brichard, A. Van-pel, T. Wolfel, J. Schneider et al., A new gene coding for a diVerentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J Exp Med, vol.180, pp.35-42, 1994.

E. De-plaen, C. Lurquin, B. Lethe, P. Van-der-bruggen, V. Brichard et al., IdentiWcation of genes coding for tumor antigens recognized by cytolytic T lymphocytes, Methods, vol.12, pp.125-142, 1997.

B. Dreno, J. M. Nguyen, A. Khammari, M. C. Pandolwno, M. H. Tessier et al., Randomized trial of adoptive transfer of melanoma tumor-inWltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunol Immunother, vol.51, pp.539-546, 2002.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, vol.298, pp.850-854, 2002.

T. Espevik and J. Nissen-meyer, A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes, J Immunol Methods, vol.95, pp.99-105, 1986.

E. Godefroy, A. Moreau-aubry, E. Diez, B. Dreno, F. Jotereau et al., ) alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen, J Exp Med, vol.202, pp.61-72, 2005.

L. Granziero, S. Krajewski, P. Farness, L. Yuan, M. K. Courtney et al., Adoptive immunotherapy prevents prostate cancer in a transgenic animal model, Eur J Immunol, vol.29, pp.1127-1138, 1999.

P. D. Greenberg, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv Immunol, vol.49, pp.281-355, 1991.

Y. Guilloux, S. Lucas, V. G. Brichard, A. Van-pel, C. Viret et al., A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene, J Exp Med, vol.183, pp.1173-1183, 1996.

H. L. Hanson, D. L. Donermeyer, H. Ikeda, J. M. White, V. Shankaran et al., Eradication of established tumors by CD8+ T cell adoptive immunotherapy, Immunity, vol.13, pp.265-276, 2000.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin et al., Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modiWed virus-speciWc T lymphocytes, Nat Med, vol.2, pp.551-555, 1996.

F. Jotereau, M. C. Pandolwno, D. Boudart, E. Diez, B. Dreno et al., High-fold expansion of human cytotoxic T-lymphocytes speciWc for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, pp.405-411, 1991.

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by Xow cytometry, J Immunol Methods, vol.159, pp.197-207, 1993.

Y. Kawakami, N. Dang, X. Wang, J. Tupesis, P. F. Robbins et al., Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor inWltrating T lymphocytes from 123 patients with melanoma, J Immunother, vol.23, pp.17-27, 2000.

Y. Kawakami, S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang et al., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-inWltrating T lymphocytes associated with in vivo tumor regression, J Immunol, vol.154, pp.3961-3968, 1995.

N. Labarriere, M. C. Pandolwno, N. Gervois, A. Khammari, M. H. Tessier et al., Therapeutic eYcacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunol Immunother, vol.51, pp.532-538, 2002.

V. Lennerz, M. Fatho, C. Gentilini, R. A. Frye, A. Lifke et al., The response of autologous T cells to a human melanoma is dominated by mutated neoantigens, Proc Natl Acad Sci, vol.102, pp.6013-6018, 2005.

B. Linard, S. Bezieau, H. Benlalam, N. Labarriere, Y. Guilloux et al., A ras-mutated peptide targeted by CTL inWltrating a human melanoma lesion, J Immunol, vol.168, pp.4802-4808, 2002.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann et al., Survival and tumor localization of adoptively transferred Melan-A-speciWc T cells in melanoma patients, J Immunol, vol.170, pp.2161-2169, 2003.

S. Mitsuma, H. Yoshizawa, K. Ito, H. Moriyama, M. Wakabayashi et al., Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells, Immunology, vol.83, pp.45-51, 1994.

A. Moreau-aubry, L. Guiner, S. Labarriere, N. Gesnel, M. C. Jotereau et al., A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma, J Exp Med, vol.191, pp.1617-1624, 2000.

L. Novellino, C. Castelli, and G. Parmiani, A listing of human tumor antigens recognized by T cells, Cancer Immunol Immunother, vol.54, pp.187-207, 2004.

M. C. Pandolwno, N. Labarriere, M. H. Tessier, A. Cassidanius, S. Bercegeay et al., High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement, Cancer Immunol Immunother, vol.50, pp.134-140, 2001.

P. F. Robbins, M. E. Dudley, J. Wunderlich, M. El-gamil, Y. F. Li et al., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy, J Immunol, vol.173, pp.7125-7130, 2004.

S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-inWltrating lymphocytes, Science, vol.233, pp.1318-1321, 1986.

M. A. Roskrow, N. Suzuki, Y. Gan, J. W. Sixbey, C. Y. Ng et al., Epstein-Barr virus (EBV)-speciWc cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease, Blood, vol.91, pp.2925-2934, 1998.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of speciWc tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J Immunol, vol.160, pp.1750-1758, 1998.

V. Vignard, B. Lemercier, A. Lim, M. C. Pandolwno, Y. Guilloux et al., Adoptive transfer of tumor-reactive Melan-A-speciWc CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-speciWc T cells, J Immunol, vol.175, pp.4797-4805, 2005.

C. Yee, J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche et al., Adoptive T cell therapy using antigen-speciWc CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor eVect of transferred T cells, Proc Natl Acad Sci, vol.99, pp.16168-16173, 2002.

J. Zhou, X. Shen, J. Huang, R. J. Hodes, S. A. Rosenberg et al., Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy, J Immunol, vol.175, pp.7046-7052, 2005.